University of PittsburghUniversity of Pittsburgh
Startups
TechnologiesStartupsExpress LicensesCollectionsChat with AI
Sign in
University of Pittsburgh

DeepRx, Inc.

OverviewRequest InfoMore Like ThisExpress Licenses

Sector

IT & Software

Therapeutic Areas

Oncology

Funding Stage

Seed

Founders

Xinghua LuGregory F. CooperLujia Chen

Website

https://www.deeprx.ai/
DeepRx, Inc.

DeepRx develops artificial intelligence tools to help match cancer patients with treatments suited to their individual tumor biology. Its clinical decision-support platform predicts responses to chemotherapy, targeted drugs and immunotherapies. The lead product, COLOXIS, focuses on helping clinicians select treatment for colorectal cancer by estimating the benefit of oxaliplatin. [1] [2]

Co-founded in 2019 by University of Pittsburgh researchers Xinghua Lu, Gregory F. Cooper and Lujia Chen, DeepRx brings biomedical informatics into precision oncology. Its work on COLOXIS has been published in the Journal of Clinical Oncology, and an angel seed investment from practicing oncologists supports further validation of the technology. [1] [3]

Discover More with AI